Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.630
+0.180 (12.41%)
At close: Jun 26, 2026, 4:00 PM EDT
1.620
-0.010 (-0.61%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Entera Bio Employees
As of December 31, 2025, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the previous year.
Employees
22
Change (1Y)
2
Growth (1Y)
10.00%
Revenue / Employee
n/a
Profits / Employee
-$562,591
Market Cap
80.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| Pliant Therapeutics | 49 |
| Elicio Therapeutics | 33 |
| Gain Therapeutics | 21 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
ENTX News
- 3 days ago - Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewsWire
- 4 days ago - Entera Bio gets FDA feedback on registrational protocol for EB613 - TheFly
- 4 days ago - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 10 days ago - Entera Bio and Opko Health present preclinical data for oral peptides - TheFly
- 10 days ago - Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 - GlobeNewsWire
- 11 days ago - ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - GlobeNewsWire
- 23 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 23 days ago - Entera Bio Proxy statement: Proxy filing - Filings